Drugs / Ilinotecan
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06464614 Background | Jul 2024 → Aug 2025 overdue | esophageal cancer | The First Affiliated Hospital of Henan University of Science and Technology | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ilinotecan | “Ilinotecan: 125mg/m2 intravenously, D1, D8, q3w, 4-6 cycles; Capecitabine, 625 mg/m2 orally, d1-14, q3w; continued until disease progression, intolerable toxicity, or...” NCT06464614 ↗ |
| Route | Intravenous | “Ilinotecan: 125mg/m2 intravenously” NCT06464614 ↗ |